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Introduction
Rho GTPases (e.g., RhoA, Rac1, and Cdc42) are key regula-
tors of normal and tumor cell migration via the control of cell 
adhesion and cytoskeleton dynamics. In particular, RhoA is 
required through activation of its effector Rho kinase (ROCK) 
and the subsequent phosphorylation and activation of myo-
sin light chain 2 (MLC2) to induce actomyosin contractility, 
driving translocation of the cell body and retraction of the rear 
(Hall, 1998; Ridley, 2001). Accordingly, the expression and ac-
tivity of RhoA (and its close relative RhoC) and ROCK have 
been directly linked with invasion and metastasis (Clark et al., 
2000; Sahai and Marshall, 2002; Croft et al., 2004; Hakem 
et al., 2005). However, the spatiotemporal activity of RhoA 
must be tightly regulated because it may also negatively in-
fl  uence cell migration and invasion by increasing stress fi  ber–
  dependent adhesions to the substrate (Cox et al., 2001; Vial 
et al., 2003). Therefore, it is important to identify the factors 
regulating RhoA activity and expression and their precise role in 
the processes of cell migration, invasion, and metastasis. In this 
context, it was recently shown that RhoA is locally targeted for 
proteasomal degradation at the cell leading edge by Smurf1, which 
is an E3-ubiquitin ligase of the C2-WW-HECT domain class. 
Smurf1 is recruited and activated at the leading edge by the 
Cdc42-activated polarity complex (PAR6-aPKC). This local 
degradation permits the correct extension of cellular protru-
sions and the establishment of cell polarity necessary for cell 
movement (Wang et al., 2003). We show that, in tumor cells, 
Smurf1 promotes lamellipodia formation and migration by speci-
fi   cally down-regulating RhoA activity and the downstream 
ROCK–MLC2 signaling pathway at the cell periphery. We next 
analyzed the potential function of Smurf1 in tumor invasion as 
a regulator of Rho signaling. We show that Smurf1 favors the 
protrusive, mesenchymal mode of invasion in 3D models and 
in vivo, in agreement with our 2D results. However, its inhibi-
tion does not block cell movement, but in contrast, induces the 
mesenchymal–amoeboid transition, which we demonstrate is 
associated with a more invasive phenotype. Thus, our work sug-
gests that Smurf1, through its regulation of RhoA signaling, is a 
pivotal regulator of tumor cell movement in vitro and in vivo.
Results and discussion
To characterize the role of Smurf1 in MDAMB-231 breast cancer 
cells, we reduced its expression by using siRNAs or short hair-
pin RNAs (shRNAs) targeting different sequences in the smurf1 
gene (Fig. 1 a). siRNA (Fig. 1 b) or shRNA (Fig. 1 c) silencing 
was accompanied by cell rounding, a reduction in size, and 
a loss of membrane protrusions. Accordingly, silenced cells 
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  displayed cortical actin staining, but the typical actin-rich la-
mellipodial extensions seen in control cells disappeared. In 
addition, some cells displayed bleblike structures typical of high 
Rho activity (Sahai and Marshall, 2003) with no effect on cell 
viability (unpublished data). These results confi  rm that Smurf1 
expression is required for the formation of cellular protrusions; 
more precisely, we show in carcinoma cells that Smurf1 is re-
quired for the extension of lamellipodia. Although no substan-
tial change in the overall accumulation of total RhoA or active 
GTP-bound RhoA could be observed in the Smurf1-silenced 
cells (Fig. 1 d), immunostaining studies showed a localized ac-
cumulation of RhoA in small areas at the cell periphery, particu-
larly in some blebs (Fig. 1 e). The absence of a detectable 
change in the overall levels of RhoA might be explained by the 
presence of a large intracellular pool of RhoA unaltered by 
Smurf1 silencing. To test whether the pool of RhoA accumu-
lated at the cell periphery is active, and therefore able to affect 
downstream signaling, we used an in situ probe for evaluation 
of the spatial Rho activity (Goulimari et al., 2005). Although the 
majority of control cells only showed an intracellular cytoplas-
mic active Rho localization (C3 treatment to inactive endoge-
nous Rho proteins in control cells revealed that the staining of 
the nucleus and perinuclear region was nonspecifi  c; unpub-
lished data), most of the Smurf1-silenced cells displayed nu-
merous dense patches of active Rho at the cell periphery, which 
is consistent with the accumulation of RhoA protein (Fig. 1 f). 
Furthermore, we observed that the activation of Rho was ac-
companied with a recruitment of ROCK1 at the cell periphery, 
together with an accumulation of phosphorylated, active MLC2 
(Fig. 1 g). In an extension of the work of Wang et al. (2003), we 
conclude that Smurf1 down-regulates RhoA activity and the 
downstream ROCK–MLC2 signaling at the cell periphery.
Figure 1.  Smurf1 is required for lamellipodia formation in carcinoma cells. (a) Cell extracts from MDAMB-231 cells transfected with control and Smurf1-
directed siRNAs and shRNAs were immunoblotted for the indicated proteins. (b) Control or Smurf1 siRNA–silenced MDAMB-231 cells were stained for 
F-actin. (c) Control or Smurf1 shRNA–silenced MDAMB-231 cells were stained for F-actin. (d) In control and Smurf1-silenced MDAMB-231 cells, levels of 
total and active pull-downed, GTP-bound RhoA, as well as the total amount of Smurf1 and β-actin, were determined by immunoblotting. (e) Control and 
Smurf1-silenced MDAMB-231 cells were stained for F-actin and RhoA. Arrows point to RhoA staining in blebs. (f) Level of active Rho was evaluated in con-
trol and Smurf1-silenced cells by analyzing GFP ﬂ  uorescence after addition of a RBD(rhotekin)-GFP probe that only binds active GTP-bound Rho, or addition 
of a control GFP probe. (g) Control and Smurf1-silenced MDAMB-231 cells were stained for ROCK1, p(S19)-, and p(T18/S19)-MLC2. Arrows point to ex-
amples of peripheral ROCK and phospho-MLC staining.SMURF1 REGULATES TUMOR CELL MOTILITY IN VIVO • SAHAI ET AL. 37
To test whether this was responsible for the phenotype 
observed in the Smurf1-silenced cells, we fi  rst used a cell-
  permeable C3 toxin (tat-C3) known to ribosylate and inhibit 
Rho protein activity. As expected, lamellipodia were restored, 
and blebs and cortical actin disappeared in cells treated with a 
low dose of C3 (25 nM; Fig. 2 a). In both control and silenced 
cells, a high dose of C3 (>100 nM) resulted in the collapse of 
the actin cytoskeleton, which is consistent with a total inhibition 
of Rho activity and the formation of abnormal protrusions, as 
previously described (Worthylake and Burridge, 2003). RhoA 
is polyubiquitylated by Smurf1 on its conserved lysine 6 
(Ozdamar et al., 2005), which is also present in RhoC. To test 
whether the phenotype of Smurf1-silenced cells is caused by a 
regulation of RhoA levels, but not of RhoC, we used siRNAs 
specifi  cally targeting RhoA. We showed that the rounded pheno-
type and the appearance of pMLC-rich blebs are specifi  cally 
antagonized by the RhoA siRNAs (Fig. 2 b); interestingly, we 
did not observe the more dramatic phenotype observed with 
100 nM C3 treatment, suggesting that at high doses, C3 inhibits 
Rho GTPases in addition to RhoA. Similar experiments using 
siRNAs against RhoC did not produce any reversion of the 
Smurf1-silencing phenotype (unpublished data). Inhibition of 
ROCK using the synthetic inhibitor Y-27632 resulted in a phe-
notype similar to that observed with high doses of C3 (Fig. 2 c). 
Because MLC can also be activated by kinases other than ROCK 
(e.g., MLC kinase and MRCK), we showed that C3 and Y-27632 
Figure 2.  The activation of peripheral RhoA–ROCK–MLC2 signaling in Smurf1-silenced cells is responsible for the loss of lamellipodia. (a) Control or 
Smurf1-silenced MDAMB-231 cells were stained for F-actin; tat-C3 was added for 24 h. (b) Smurf1- and/or RhoA-silenced MDAMB-231 cells were stained 
for F-actin and p(S19)-MLC2. (c) Control or Smurf1-silenced MDAMB-231 cells were stained for F-actin, RhoA, and p(S19)-MLC2; 25 nM tat-C3 or 5 μM 
Y-27632 was added for 24 h. (d) Control or Smurf1-silenced MDAMB-231 cells were stained for F-actin; blebbistatin was added for 60 min.JCB • VOLUME 176 • NUMBER 1 • 2007  38
treatments also abolished the phosphorylation of MLC2 seen in 
Smurf1-silenced cells, indicating that it was Rho- and ROCK- 
dependent (Fig. 2 c). We next showed that blebbistatin, which is 
a nonmuscle myosin ATPase inhibitor, also rescued the effect of 
Smurf1 silencing (Fig. 2 d), suggesting that the absence of pro-
trusion, the rounding, and the appearance of blebs are at least 
partially caused by an increase in peripheral actomyosin con-
tractility. Importantly, we further confi  rmed the central role of 
Rho signaling by showing that Smurf1 silencing in tumor cells 
does not affect the other ubiquitylation targets of Smurf1, such 
as the SMAD proteins involved in the transcriptional response 
to TGFβ (Fig. S1 a, available at http://www.jcb.org/cgi/content/
full/jcb.200605135/DC1; Izzi and Attisano, 2004) and the 
MEKK2–JNK signaling pathway (Fig. S1 b; Yamashita et al., 
2005). Altogether, our work demonstrates that the activation of 
RhoA–ROCK–MLC2 signaling at the cell periphery observed 
in the Smurf1-silenced cells, and the consequent increase in ac-
tomyosin contractility, is responsible for the loss of lamellipodia 
and the formation of blebs.
To evaluate the consequence of these morphological modi-
fi  cations on the invasive phenotype, we fi  rst monitored the ran-
dom motility of MDAMB-231 cells upon Smurf1 silencing. 
Cell migration was reduced by  80%; it was partially restored 
C3 and Y-27632 treatments (Fig. 3 a). These results, together 
with the regulation of Rho signaling, were reproduced in BE 
and HT1080 tumor cells (unpublished data). Consistently, cell 
migration was also inhibited by overexpression of two Smurf1-
interfering mutants: Smurf1-C699A, which is defi  cient in its 
ubiquitin ligase activity (Wang et al., 2003), and Smurf1-∆C2, 
which fails to localize at the plasma membrane (Fig. 3 b; Suzuki 
et al., 2002). As for Smurf1 silencing, both mutants induced cell 
rounding, loss of membrane protrusions, blebbing, and accumu-
lation of RhoA at the cell periphery (Fig. 3 c). Notably, C3 and 
Y-27632 treatments in control cells did not signifi  cantly affect 
cell migration. One possibility is that in MDAMB-231 cells, the 
actomyosin contractility necessary for cell movement is also 
generated by the Cdc42–MRCK pathway (Wilkinson et al., 
2005). These results indicate that RhoA–ROCK–MLC2 signaling 
is not essential for MDAMB-231 cell movement in 2D, and, 
more importantly, that it needs to be specifi  cally inhibited by 
Smurf1 at the cell periphery to allow the formation of protrusions 
and tumor cell migration. The lowering of myosin-dependent 
contractile signals at the cell edge is probably required to di-
minish the local tension and adhesive forces, allowing the Rac-
driven extension of the lamellipodium. The localized nature of 
Smurf1 activity permits it to maintain the intracellular Rho–
ROCK–MLC2 activity, which is likely to be required for contrac-
tion of the cell body and retraction of the rear (Fig. S2, avail  able 
at http://www.jcb.org/cgi/content/full/jcb.200605135/DC1).
In contrast to the situation in 2D tissue culture, there are 
several mechanisms of tumor cell migration in vivo and in 3D 
models of invasion (Friedl and Wolf, 2003; Sahai, 2005). The 
protease-dependent mesenchymal mode of movement needs 
low activities of RhoA and ROCK to allow, as seen in 2D, the 
extension of Rac-dependent protrusions at the front (Vial et al., 
2003). On the contrary, the second main mode of motility, called 
amoeboid, is protease independent, but depends on high activi-
ties of Rho, ROCK, and MLC2 to generate cortical contractile 
forces used for matrix deformation; it does not extend protru-
sions and it is associated with a more rounded morphology 
(Sahai and Marshall, 2003; Wyckoff et al., 2006). Importantly, 
cancer cells can switch from one mode of movement to another, 
depending on the 3D microenvironment. Rho signaling is piv-
otal because its blockade induces the mesenchymal–amoeboid 
transition and, conversely, its constitutive activation leads to a 
conversion to the amoeboid mode of movement. To analyze the 
role of Smurf1 in invasion, we fi  rst studied cell motility in 3D 
Matrigel matrices in vitro. We used the previously described 
Figure 3.  Smurf1 is required for tumor cell 
migration in 2D. (a) Random migration speed 
of control or Smurf1-silenced MDAMB-231 
cells was averaged over a 6-h period of cell 
tracking by phase-contrast time-lapse micros-
copy. 10 μM Y-27632 or 0.5 μM tat-C3 was 
added to the medium 24 h before analysis. 
n = 3; mean ± the SD. At least 25 cells were 
analyzed in each experiment. P values of t test 
are indicated. (b) 48 h after transfection of 
p-EGFP-N1 alone or together with interfering 
Smurf1-C699A and Smurf1-∆C2 mutants, 
EGF-expressing MDAMB-231 cells were 
tracked over a 6-h period by time-lapse micros-
copy for analysis of random migration. n = 2; 
mean ± the SD; at least 25 cells were ana-
lyzed in each experiment; P values of t test are 
indicated. (c) Alternatively, transfected cells 
were ﬁ  xed and stained for F-actin and RhoA. 
Arrows indicate transfected cells.SMURF1 REGULATES TUMOR CELL MOTILITY IN VIVO • SAHAI ET AL. 39
mesenchymal BE colon carcinoma cells, which display low 
RhoA activity, and the amoeboid A375m2 melanoma cells with 
high RhoA activity (Figs. 4, a and b; Sahai and Marshall, 2003). 
When Smurf1 was silenced in A375m2 cells, the morphology 
and the invasion of the 3D matrix were unaltered, as most of the 
cells kept the rounded phenotype (Fig. 4 c). In contrast, silencing 
of Smurf1 in BE cells resulted in a dramatic transition from 
the mesenchymal to the amoeboid morphology and mode of in-
vasion, which was partially reversed by treatment with Y-27632. 
These results suggest that in cancer cells, Smurf1 expression, 
through the local down-regulation of RhoA–ROCK activity and 
the formation of cellular protrusions, favors the mesenchymal 
mode of invasion in 3D.
We next asked if Smurf1 would also be required for the 
mesenchymal morphology in an in vivo tumor environment and 
what would be its impact on invasion. To trigger stable and 
long-term inhibition of Smurf1 in vivo, we generated BE tumor 
cell lines stably expressing GFP and shRNAs against Smurf1 
(Fig. 5 a). As seen with BE and MDAMB-231 cells transiently 
expressing the siRNAs against Smurf1, these clones showed a 
reduced cell motility in 2D and displayed the amoeboid pheno-
type in Matrigel (unpublished data). BE clones were grown as 
subcutaneous tumors in nude mice, and multiphoton intravital 
microscopy was used on living animals to analyze tumor cell 
morphology and movement. In vivo, BE cells expressing the 
control shRNA had an overall elongated morphology, whereas 
cells expressing the Smurf1 shRNAs were mostly rounded, con-
fi  rming our in vitro observations (Fig. 5 b). In agreement, in the 
control tumors, time-lapse intravital imaging showed that the 
moving cells used the mesenchymal mode of motility by ex-
tending protrusions at the front. Interestingly, only a minority of 
cells was migrating, but even the static cells presented the elon-
gated morphology (Fig. 5 c; Video 1), indicating that additional 
factors intrinsic to the tumor microenvironment are required to 
promote cell movement. In the Smurf1-silenced tumors, all 
cells were rounded, particularly those migrating, thus confi  rming 
that they were using the amoeboid motility (Fig. 5 c; Video 2). 
These data demonstrate that in tumors, Smurf1 favors the mes-
enchymal mode of invasion, and that its inhibition induces the 
mesenchymal–amoeboid transition in agreement with the acti-
vation of Rho-dependent contractile signals in 2D. Interestingly, 
although previous studies showed that the different modes of 
invasion and the plasticity between those were characterized 
and regulated by the general level of RhoA–ROCK–MLC2 ac-
tivity in the cells (Sahai and Marshall, 2003; Wyckoff et al., 
2006), our work shows that subtle changes at the cell periphery 
induced by Smurf1, which were undetectable at the biochemical 
level, are suffi  cient to induce the transition in the invasion strat-
egies. Factors that can regulate either Smurf1 expression or its 
activity in the process of tumor development are therefore po-
tential key elements in the plasticity of cancer cell invasion. 
This is important because the plasticity between the different 
modes of movement allows tumor cells to be highly adaptable 
to the dynamic microenvironment in cancer, and it might pro-
vide an escape mechanism to antiinvasive treatments (Friedl 
and Wolf, 2003).
Finally, we sought to analyze the impact of Smurf1 silenc-
ing on the effi  ciency of cell movement, invasion, and  metastasis. 
Intravital analyses revealed that upon Smurf1 silencing there 
were approximately three times as many cells migrating, 
indicating that the transition to the amoeboid mode movement 
signifi   cantly increases cell motility in tumors (Fig. 5 d). 
Strikingly, although control cells were never seen in tumor vessels 
(blood or lymphatic), Smurf1-silenced amoeboid BE cells were 
Figure 4. Smurf1 silencing induces the 
mesenchymal–amoeboid transition in 3D ma-
trices in vitro. (a) BE and A375m2 cells ex-
pressing GFP and embedded within a thick 3D 
Matrigel matrix were imaged after ﬁ  xation by 
capturing at least 30 confocal sections. These 
were subsequently reconstructed in 3D using 
Volocity imaging software. (b) Levels of total 
and active pull-downed, GTP-bound RhoA from 
control and Smurf1-silenced BE and A375m2 
cells were determined by immunoblotting. (c) 
Control or Smurf1-silenced BE and A375m2 
cells expressing GFP were allowed to invade a 
thick 3D Matrigel matrix for 96 h; for ROCK 
inhibition, 5 μM Y-27632 was added to the 
medium every day. Only cells that invaded 
a minimum of 10 μm inside Matrigel 
were scored as invasive and analyzed for 
morphology by confocal sectioning and 3D 
reconstruction. The ratio of amoeboid cells to 
mesenchymal cells is shown on the left, as well 
as representative 3D reconstructions. One 
representative experiment out of two is shown.JCB • VOLUME 176 • NUMBER 1 • 2007  40
often imaged in the vessels or intravasating (Figs. 5, b and e; 
Videos 3 and 4). The number of blood vessels was unaffected by 
Smurf1 silencing (Fig. S3). However, the growth of Smurf1-
  silenced or control subcutaneous tumors never resulted in the 
formation of visible distant metastases, indicating that in this 
model additional factors are needed for BE cells to effi  ciently 
metastasize. Nevertheless, to test whether Smurf1-silencing 
could also affect the later stages of cancer dissemination, we in-
jected tumor cells directly into the tail vein of immunodefi  cient 
mice for measurement of lung metastases. As for the subcutaneous 
model, we found that BE cells did not readily metastasize and 
that Smurf1-silencing did not increase metastasis (unpublished 
data). Collectively, these data show that Smurf1 knockdown 
and the mesenchymal–amoeboid transition in tumors increases 
tumor cell motility and favors intravasation, but it is not suffi  -
cient to promote metastasis after cells have entered the vessels. 
Our results are in agreement with previous work (Wang et al., 
2002), showing that mesenchymal cells often fragment when 
they enter the blood stream and that, instead, highly metastatic 
carcinoma cells effi  ciently crawl into the blood vessels by using 
the amoeboid locomotion. It is worth noting that the effi  ciency 
of tumor cell motility in 2D therefore does not necessarily re-
fl  ect the invasive potential in vivo.
In conclusion, our work demonstrates that Smurf1, through 
the regulation of peripheral RhoA–ROCK–MLC2 signaling, 
is a key element of tumor cell motility and invasion in vitro, 
Figure 5.  Smurf1 silencing induces the mesenchymal–amoeboid transition in vivo and increases invasion and intravasation. (a) Cell extracts from indepen-
dent BE clones stably expressing GFP and the control or Smurf1 shRNAs were immunoblotted for the indicated proteins. (b) Control and Smurf1-silenced 
BE-GFP clones were injected subcutaneously to form a tumor xenograft. Morphology of GFP-expressing tumor cells was analyzed in vivo using multiphoton 
intravital microscopy. Tumor cells are shown in green, and collagen ﬁ  bers of the tumor stroma are shown in red. Arrows indicate tumor vessels; asterisk 
shows tumor cells in vessels. (c) Movement of tumor cells was imaged over time in vivo using multiphoton intravital microscopy (Videos 1 and 2). 90-s sepa-
rated frames are shown (left). Movement of one individual tumor cell is indicated by an arrow. Polarity index (as an evaluation of the mesenchymal or 
amoeboid morphology) of static and moving tumor cells within the tumor is shown on the right. P values of t tests are indicated. (d) Cell motility was evaluated 
quantitatively by measuring the mean number of moving cells per microscope ﬁ  eld in the control or Smurf1-silenced tumors. (e) The presence of tumor cells 
in vessels was imaged and quantiﬁ  ed using intravital multiphoton microscopy (Video 3 and 4). Data are derived from analysis of 14 control BE tumor videos 
and 18 BE Smurf1 shRNA videos. Videos 1–4 are available at http://www.jcb.org/cgi/content/full/jcb.200605135/DC1.SMURF1 REGULATES TUMOR CELL MOTILITY IN VIVO • SAHAI ET AL. 41
as well as in vivo. Recent data have suggested that Smurf1 activity 
can be activated by TGFβ in normal epithelial cells to induce 
the degradation of RhoA at the tight junctions, leading to the 
dissolution of these cell–cell junctions and the subsequent 
TGFβ-dependent epithelial–mesenchymal transition (Ozdamar 
et al., 2005). We hypothesize that Smurf1 could be implicated in 
two crucial aspects of tumor progression in a Rho-dependent 
manner; in the fi  rst stages of the invasive progression, Smurf1 
might be activated by TGFβ to disrupt normal epithelial organi-
zation (Ozdamar et al., 2005). In carcinomas that have lost their 
epithelial organization, such as those analyzed in this study, 
down-regulation of Smurf1 expression or activity would then 
increase motility. Investigation of the “Oncomine” resource 
(www.oncomine.org) shows that overall Smurf1 levels do not 
change greatly with tumor grade or prognosis; however, this is 
entirely consistent with our results, which indicate that reduc-
tion of Smurf1 facilitates cell motility and intravasation specifi  -
cally, and not the entire metastatic process.
Materials and methods
Cell lines and plasmids
MDAMB-231 breast cancer cells, BE and LS174T colon carcinoma cells, 
A375m2 melanoma cells, and HT1080 ﬁ  brosarcoma cells were gifts from 
C.J. Marshall (Institute of Cancer Research, London, UK). Stable GFP-
  expressing clones were selected after transfection of pEGFP-N1 (CLONTECH 
Laboratories, Inc.). Cells were routinely maintained in DME supplemented 
with 10% FCS. cDNAs for the human Smurf1-interfering mutants Smurf1-
C699A and -∆C2 were gifts from J. Wrana (University of Toronto, Toronto, 
Canada). SBE4 reporter construct was a gift from B. Vogelstein (Johns 
Hopkins Oncology Center, Baltimore, MD). The truncated activated ROCK1 
mutant ROCK∆3 was described elsewhere (Sahai and Marshall, 2003). 
Transfections were carried out using Lipofectamine 2000 (Invitrogen) 
  according to the manufacturer’s recommendations.
Reagents and antibodies
Cell-permeable C3 (Tat-C3) was prepared as previously described (Sahai 
and Olson, 2006). Y-27632 was obtained from Tocris. Human TGFβ1 
(R&D Systems) was a gift from E. van Obberghen-Schilling (Institute of 
Signaling Developmental Biology and Cancer, Nice, France) and was used 
at 1 ng/ml. Anisomycin was used at 0.5 μg/ml, and blebbistatin was used 
at 25 μM, for 60 min. Antibodies used were as follows: Smurf1 (Santa 
Cruz Biotechnology, Inc.); RhoA (Santa Cruz Biotechnology, Inc.); β-actin 
(Sigma-Aldrich); MYC (Cell Signaling Technology); phospho-JNK1/2 
  (Promega); phospho(Ser3)-coﬁ  lin (Cell Signaling Technology); ROCK1 (Santa 
Cruz Biotechnology, Inc.). Antibodies against phospho(Ser19)-MLC2 
(Cell Signaling Technology), phospho(Thr18/Ser19)-MLC2 (Cell Signaling 
  Technology), and phospho-LIMK (Cell Signaling Technology) were gifts from 
M. Olson (Cancer Research UK Beatson Institute for Cancer Research, 
Glasgow, UK). Secondary antibodies for immunoﬂ   uorescence were ob-
tained from Promega. The RBD(rhotekin)-GFP probe was a gift from 
R. Grosse (University of Heidelberg, Heidelberg, Germany) and was used 
as previously described (Goulimari et al., 2005).
siRNAs and shRNAs
Oligonucleotides were purchased from Dharmacon and Eurogentec. The 
siRNA sequences targeting human smurf1 used were as follows: sense, 
C  C  G  A  C  A  C  U  G  U  G  A  A  A  A  A  C  A  C  dTdT; antisense, G  U  G  U  U  U  U  U  C  A  C  A  G  U-
G  U  C  G  G  dTdT. The RhoA siRNA sequences used were as follows: sense, 
G  A  A  C  U  A  U  G  U  G  G  C  A  G  A  U  A  U  C  U  U  dTdT; antisense, A  A  G  A  U  A  U  C  U  G  C  C  A-
C  A  U  A  G  U  U  C  dTdT. The control oligonucleotides targeting the Drosophila 
melanogaster hif1α gene were gifts from E. Berra (Institute of Signaling 
Developmental Biology and Cancer, Nice, France) and were previously 
described (Berra et al., 2003). siRNAs were transfected using the Oli-
gofectamine reagent (Invitrogen) according to the manufacturer’s recom-
mendations. For construction of the shRNA vectors targeting Smurf1, the 
targeted sequences in the human smurf1 gene were 5′-T  A  C  G  T  C  C  G  G  T  T  G  T-
A  T  G  T  A  A  -3′ (shRNA-1) and 5′-T  G  A  A  G  G  A  A  C  G  G  T  G  T  A  T  G  A  A  -3′ (shRNA-2). 
The corresponding oligonucleotides (sequences available upon request) 
were annealed and cloned into the shRNA-expressing vector pTER (van de 
Wetering et al., 2003). These vectors and a vector expressing a control 
shRNA (gift from E. Berra) were transfected into MDAMB-231 cells for tran-
sient expression of the shRNAs, or into BE cells for the generation of stable 
cell lines constitutively expressing the shRNAs. All the shRNA transfections 
were done using Lipofectamine 2000.
Immunoblotting, Rho pull-down assays, and immunocytochemistry
Whole-cell extracts were harvested in 1.5× Laemmli sample buffer, and 
immunoblotting was performed using standard procedures. RhoA pull-
down assays were performed using GST-rhotekin, as previously described 
(Sahai et al., 2001); levels of total and active RhoA were revealed using a 
RhoA-speciﬁ  c antibody (Santa Cruz Biotechnology, Inc.). For immunoﬂ  uo-
rescence, cells were washed with PBS, ﬁ  xed with 4% paraformaldehyde in 
PBS, and permeabilized with 0.2% Triton X-100 in PBS. After several PBS 
washes, cells were either stained for the actin cytoskeleton with Alexa Fluor 
568–phalloidin (Invitrogen) or primary antibodies were added for 2 h; 
after several PBS washes, appropriate secondary antibodies conjugated to 
Alexa Fluor 488, 568, or 647 were added for 1 h; cells were mounted 
after several additional PBS washes and viewed using a microscope 
(Axiovert 200) with Plan Apochromat 63×/1.4 NA oil or Plan Neoﬂ  uor 
40×/1.3 NA oil objectives, a camera (HAL100), and Immersol medium 
with Ne = 1,518 (all from Carl Zeiss MicroImaging, Inc.).
Luciferase assays
For analysis of luciferase activity, transfected cells were lysed in 25 mM 
Tris-phosphate, pH 7.8, 2 mM DTT, 2 mM 1,2-diaminocyclohexane-
N,N,N′,N′-tetraacetic acid, 10% glycerol, and 1% Triton X-100. Light 
emission was quantiﬁ  ed using a luminometer (1450 Microbeta; Wallac) 
after addition of the luciferase substrate (20 mM Tricine, 1.07 mM 
(MgCO3)4Mg(OH)2.5H2O, 2.67 mM MgSO4, 0.1 mM EDTA, 33.3 mM 
DTT, 0.27 mM coenzyme A, 0.47 mM luciferin, and 0.53 mM ATP). As a 
control, β-galactosidase activity was quantiﬁ  ed in the lysate using the 
Galacton Substrate kit (Tropix; Applied Biosystems).
Migration and invasion assays in vitro
The 2D motility of cells was analyzed by recording phase-contrast or GFP 
ﬂ   uorescence images with a multichannel time-lapse digital video micro-
scope for several hours (Axiovert 200, 10×/0.25 NA plan Ph/VAR dry 
objective, HAL100 camera; incubation chamber at 37°C, 5% CO2). Cell 
speed was determined by tracking cells with MetaMorph Software (Universal 
Imaging Corp.). The 3D morphology was analyzed by embedding tumor 
cells within a thick Matrigel matrix. After an 18-h incubation, cells were 
ﬁ  xed in 4% paraformaldehyde and imaged by capturing at least 30 confo-
cal sections of GFP ﬂ  uorescence (SPI TCSNT confocal microscope [Leica]; 
Plan Apochromat 40×/1.3 NA oil objective; immersion oil #11513859 
[Leica] with Ne = 1,518). These were subsequently reconstructed in 3D 
using Volocity software (Improvision). The 3D invasion assays were per-
formed as previously described (Malliri et al., 1998). In brief, cells were 
allowed to attach to the underside (bottom) of the growth factor–depleted 
Matrigel-coated polycarbonate chambers (Transwells; 8-μm pore-size 
ﬁ  lters). The cells were then chemoattracted (10% FCS) across the ﬁ  lter and 
through the Matrigel above it. Cells were ﬁ  xed in 4% paraformaldehyde, 
and GFP ﬂ  uorescence was analyzed in z sections (one section every 4 μm) 
from the bottom of the ﬁ  lter, using a confocal microscope. 3D reconstruc-
tions of the GFP-expressing cells into the Matrigel were done using Volocity 
computer software. Cells were scored as amoeboid when the polarity in-
dex (long axis/short axis ratio) was less than two, with no apparent cel-
lular protrusions.
In vivo imaging of tumor xenografts
10
6 tumor cells were injected subcutaneously into the ﬂ  ank of young adult 
immune-compromised mice. Once tumors were established (diam 4–7 mm), 
intravital imaging of tumor cell morphology and movement was performed 
on living anesthetized animals using two-photon microscopy, as described 
elsewhere (Sahai et al., 2005). The animal study protocols were conducted 
according to approved institutional guidelines for animal use. Tumors were 
ﬁ  xed in 4% paraformaldehyde after imaging and stained for endomucin 
(details available on request) to reveal the presence of blood vessels.
Online supplemental material
Fig. S1 shows that Smurf1 does not interfere with SMAD or JNK activity 
in carcinoma cells. Fig. S2 shows the overall activity of downstream ef-
fectors of the Rho–ROCK pathway upon Smurf1 silencing. Fig. S3 shows JCB • VOLUME 176 • NUMBER 1 • 2007  42
that Smurf1 silencing does not affect the vessel density in tumors. Video 1 
shows a mesenchymal BE tumor cell moving in the tumor by extending 
a protrusion at the front. Video 2 shows rounded Smurf1-silenced BE 
tumor cells moving in the tumor with no protrusions, indicating that 
they are using the amoeboid mode of locomotion. Video 3 shows that 
mesenchymal BE tumor cells are not highly motile and that no tumor cells 
are seen in the vessels. Video 4 shows that amoeboid Smurf1-silenced 
BE tumor cells are highly motile and that many cells are visible in the 
vessels. Online supplemental material is available at http://www.jcb.
org/cgi/content/full/jcb.200605135/DC1.
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